Floatz logo

Gnc-035

Non-hodgkin's Lymphoma

Sichuan Baili Pharmaceutical Co., Ltd.monoclonal_antibodyPhase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
73/ 100

Competitive context

410 Active assets in the Non-hodgkin's Lymphoma cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
Memorial Sloan Kettering Cancer Center
Phase 3BBB
PEGASPARGASE
Ciusss de L'Est de l'Île de Montréal
Phase 4BBB
Inno-206
National Cancer Institute (NCI)
Phase 4BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Mwanasha Merrill, MD
Phase 3BBB
Entecavir
Fudan University
Phase 4BBB

View all 50 →

Same molecule, other indications

Gnc-035 is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
CCC
Indicative ·
48 / 100
View asset →
hematopoietic and lymphoid system neoplasmDormant
C
Indicative ·
39 / 100
View asset →
breast cancerDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →